# Obsidian Therapeutics, Inc. (OBX)

> Source: Nexqual · https://nexqual.com/OBX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Obsidian Therapeutics, Inc. (OBX), nexqual.com/OBX" · informational, not investment advice.

**Price:** USD 12.2 (-0.16% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 12.22 · day 12.06–12.67 · 52w 11.79–49.97 · market cap $754M · NCM

## Key facts
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 39 (range 32–43).
- Total return with dividends: 1Y -30.3% vs S&P 500 +18.1%; 5Y -21.9% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 39 (low 32, high 43).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | Leerink Partners | Initiated | Outperform | $32 |
| 2026-09-09 | William Blair | Initiated | Outperform |  |
| 2026-08-18 | LifeSci Capital | Initiated | Outperform | $43 |
| 2026-08-05 | Piper Sandler | Initiated | Overweight | $42 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-07-27) | 5Y (from 2026-07-27) |
|---|---|---|
| Total return | -30.3% | -21.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 188.4% | 178.7% |
| Max drawdown | -65.7% (Aug 2026→Oct 2026) | -55.6% (Aug 2026→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/OBX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt